BIO Comments On Follow-On Biologics Will Include Manufacturing Anecdotes
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA officials' questions to industry reps during public workshop focus on the level of studies that should be required for follow-on biologic applications, particularly in comparison to requirements for manufacturing process changes by innovators.
You may also be interested in...
FDA Follow-on Proteins Draft Guidance Will Be Followed By Third Public Meeting
The agency's next step on "generic" biologics is to release a background document on FDA's past regulatory and scientific treatment of protein products. The draft guidance – which could be a set of "interlocking" guidances – will be released subsequent to the background document.
FDA Follow-on Proteins Draft Guidance Will Be Followed By Third Public Meeting
The agency's next step on "generic" biologics is to release a background document on FDA's past regulatory and scientific treatment of protein products. The draft guidance – which could be a set of "interlocking" guidances – will be released subsequent to the background document.
GPhA Asks FDA To Create Task Force On Generic Biopharmaceuticals
The agency should abandon its “arbitrator” role in the face of the brand industry’s continued reluctance to discuss a path forward, GPhA maintains. FDA should put together an analysis of the issues to be presented at an upcoming FDA/DIA meeting.